




Biomedical
CONTACT: Katie Kukwa
Channel Marketing Manager
Katie.kukwa@dsm-firmenich.com
440.417.4411

[dsm-firmenich.com](https://www.dsm-firmenich.com)



August 2024

dsm-firmenich Announces Successful Defense of Patent Protecting Its Medical-Grade Colored Yarn Products

EXTON, PA – dsm-firmenich announces that the United States Patent and Trademark Office (USPTO) rejected Honeywell’s request for inter partes review (IPR) and cancellation of dsm-firmenich’s U.S. Patent No. 10,280,532, claiming a colored multi-filament yarn. The protected inventions are useful in medical devices, such as colored Ultra High Molecular Weight Polyethylene (UHMWPE) sutures.

dsm-firmenich, via its subsidiary DSM Biomedical, and Honeywell are currently engaged in a lawsuit in which dsm-firmenich has accused Honeywell’s Spectra® MG Bio Blue fibers of infringing this patent. In the lawsuit, dsm-firmenich is asking the federal court in the District of Delaware (Case # 23-675) to order that Honeywell cease manufacturing, marketing, and selling Spectra® MG Bio Blue fibers in the United States and to award dsm-firmenich financial compensation.

“We are pleased with the USPTO’s decision to uphold our patent,” said Paul Spencer, President of the Biomedical division of dsm-firmenich. “This decision reinforces the strength and validity of our patent and confirms the value of our investments in Ulteeva Purity™ UHMWPE fiber technology.”

dsm-firmenich is a world leading manufacturer of colored Ulteeva Purity™ UHMWPE fibers for the medical industry with a proven track record of success in producing fibers that meet the highest quality, purity, and consistency requirements globally. dsm-firmenich holds a broad portfolio of patents in various countries around the world and proactively monitors third-party activities for potential infringement, acting where necessary to protect against illegal use of its patented technologies.

About dsm-firmenich

As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and



renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people.

www.dsm-firmenich.com

About Biomedical

As the world's unrivaled biomaterials expert and committed partner in driving sustainable innovation in healthcare, Biomedical is at the forefront of biomaterial science and process innovation. The company's technologies and support are recognized for their unmatched quality, reliability, and performance in multiple markets worldwide. To learn more, visit dsm-firmenich.com/biomedical

Forward-looking statements

This press release may contain forward-looking statements with respect to dsm-firmenich's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM-Firmenich's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM-Firmenich and information currently available to the company. DSM-Firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM-Firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.